Praxis Precision Medicines, Inc. PRAX
305.06 USD -5.21 (-1.68%)
Regular-session close
307.00 +1.94 +0.64%
After hours · Nov 17, 7:30 PM ET
300.99 Day range 319.00
160.11 52-week range 392.70
- YTD
- +3.50%
- 1 year
- +54.40%
News
benzinga.com This Medtronic Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Analysts upgraded UNFI, ZBH, NUE, MDT and PRAX, raising price targets and ratings to Buy or Overweight.benzinga.com Wells Fargo Upgrades Praxis Precision Medicine to Overweight, Raises Price Target to $509 Wells Fargo analyst Benjamin Burnett upgrades Praxis Precision Medicine (NASDAQ:PRAX) from Equal-Weight to Overweight and raises the price target from $343 to $509.
seekingalpha.com Praxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 Transcript Praxis Precision Medicines, Inc. ( PRAX ) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants…benzinga.com Guggenheim Maintains Buy on Praxis Precision Medicine, Raises Price Target to $1050 Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $800 to $1050.
benzinga.com Baird Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $568 Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $514 to $568.
seekingalpha.com Praxis Precision Medicines: No Material Changes After Q3 And Investor Day (Rating Kept) I maintain a Strong Buy on Praxis Precision Medicines, with a $601 fair value, 85% above the November 12 close. The valuation falls from $664 primarily after correcting the share count for pre-funded…
globenewswire.com Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027
seekingalpha.com Praxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Praxis Precision Medicines, Inc. ( PRAX ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 9:30 AM EST Company Participants Marcio Souza - President, CEO & Director Tim Kelly -…benzinga.com RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $478 RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $462 to $478.
benzinga.com Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $189 Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price target from $188 to $189.
benzinga.com Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Lowers Price Target to $343 Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and lowers the price target from $362 to $343.
benzinga.com BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $826 Price Target BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $826 price target.
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
